About Zemplar Capsules
Zemplar Capsules—indicated for the prevention and treatment of SHPT associated with chronic kidney disease (CKD) in stage 3 and 4 (GFR 15-60 mL/min/1.73 m2)
Zemplar Capsules:
- A vitamin D receptor activator specifically designed to reduce PTH. In clinical trials with individualized dosing and monitoring, mean calcium and phosphorus levels were maintained within normal limits
- 91% of Zemplar Capsules-treated patients (vs 13% of the placebo-treated patients) achieved two consecutive >30% iPTH reductions from baseline in three 24-week, double-blind, placebo-controlled, randomized, multicenter clinical trials in CKD stage 3 and 4 patients
- The incidences of hypercalcemia, hyperphosphatemia, and elevated Ca x P product in the Zemplar Capsules—treated patients were similar to the placebo-treated patients
For more information, please go to the following sections:
